Adherence with adjuvant hormonal therapy for breast cancer
Open Access
- 1 March 2009
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 20 (3), 401-402
- https://doi.org/10.1093/annonc/mdp039
Abstract
Nonadherence to oral medication is an increasingly recognized concern in the care of patients with cancer [1]. In women with hormone-sensitive breast cancer, long-term daily oral hormonal therapy has been shown repeatedly in clinical trials to significantly reduce risk of recurrence and improve survival. Every year, hundreds of thousands of women worldwide are recommended to take tamoxifen (TAM) or an aromatase inhibitor for ≥5 years. Patient adherence (taking doses as prescribed) and persistence (not discontinuing the medication entirely) with these agents is essential to the ability of these treatments to improve outcomes.This publication has 6 references indexed in Scilit:
- Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancerAnnals of Oncology, 2009
- Patient adherence and persistence with oral anticancer treatmentCA: A Cancer Journal for Clinicians, 2009
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancerBritish Journal of Cancer, 2008
- Adherence to Endocrine Therapy for Breast CancerOncology, 2006
- Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast CancerJournal of Clinical Oncology, 2003
- Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring.Journal of Clinical Oncology, 1993